Albert Bourla, Pfizer CEO (Laurent Gillieron/Keystone via AP)

Break­ing: Pfiz­er in hot pur­suit of a $5B buy­out of Glob­al Blood Ther­a­peu­tics — re­port

Pfiz­er CEO Al­bert Bourla has vowed to leave no stone un­turned in the search for new biotech deals, and the BD team is not let­ting him down.

The Wall Street Jour­nal re­port­ed to­day that Pfiz­er is in the fi­nal stages of ac­quir­ing Glob­al Blood Ther­a­peu­tics for $5 bil­lion. Ac­cord­ing to the Jour­nal re­port, though, Pfiz­er is not the on­ly buy­er at the deal ta­ble and while the phar­ma gi­ant may be close to clinch­ing it, there are no guar­an­tees it will con­tin­ue.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters